Selpercatinib Retevmo shows strong efficacy in a variety of cancers
- Did Cloud Seeding Unleash a Deluge in Dubai?
- Scientists Identify Gut Bacteria and Metabolites that Lower Diabetes Risk
- OpenAI’s Model Matches Doctors in Assessing Eye Conditions
- UK: A Smoke-Free Generation by Banning Sales to Those Born After 2009
- Deadly Mutation: A New Monkeypox Variant Emerges in the DRC
- EPA Announces First-Ever Regulation for “Forever Chemicals” in Drinking Water
Selpercatinib Retevmo shows strong efficacy in a variety of cancers
- Israel new drug for COVID-19: EXO-CD24 can reduce deaths by 50%
- COVID-19 vaccines for children under 12 will be available soon
- Breakthrough infection of Delta: No difference from regular COVID-19 cases
- French research: ADE occurred in Delta variant and many doubts on it
- Deer herds in U.S. are heavily infected with the new coronavirus (COVID-19)
Selpercatinib Retevmo shows strong efficacy in a variety of cancers. These results demonstrate the potential of Selpercatinib in this patient population and reiterate the importance of extensive genome profiling to determine the role of oncogenic drivers (including RET fusion proteins).
Retevmo Selpercatinib has demonstrated encouraging anti-tumor activity in phase 1/2 LIBRETTO-001 clinical trials and across RET fusion-positive advanced solid tumors of lung cancer and cancers other than thyroid cancer, including a variety of difficult Treatment of gastrointestinal (GI) malignant tumors. Eli Lilly said that these data were submitted for the first time at the virtual 2021 American Association for Cancer Research Annual Meeting to be held from April 10 to 15, 2021.
Retevmo Selpercatinib is a selective RET kinase inhibitor. Eli Lilly’s Retevmo Selpercatinib product received accelerated FDA approval in May 2020 for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer. It is suitable for adults aged 12 years and above , Adult and pediatric patients with advanced or metastatic RET-mutant medullary thyroid cancer that require systemic treatment, as well as adults and pediatrics who are 12 years and older and have advanced or metastatic RET fusion-positive thyroid cancer Patients need systemic treatment and are refractory to radioactive iodine (radioactive iodine should be used if appropriate).
Eli Lilly Oncology Chief Medical Officer David Hyman (David Hyman) said in a prepared statement: “We are very pleased to expand Retevmo’s evidence in RET fusion-positive cancers beyond lung and thyroid tumors.” “These encouraging results, including in difficult-to-treat gastrointestinal malignancies, are increasing evidence that RET fusion may play a role in multiple types of tumors. These findings further support the broad tumor profile. The importance of analysis in advanced cancer. We look forward to discussing these new data with regulators this year.”
In the LIBRETTO-001 trial, 32 adult patients with 12 unique RET fusion-positive advanced cancer types were recruited by the efficacy deadline as of September 19, 2020, and followed up until March 19, 2021. Cancer types treated include pancreatic cancer, colon cancer, breast, saliva, sarcoma, carcinoid, rectal neuroendocrine, small intestine, xanthogenic granuloma, ovarian, lung cancer, sarcoma and unknown primary cancers. Of the 32 patients, 62.5% had GI tumors (defined as pancreas [n = 9], colon [n = 9], small intestine [n = 1], and rectal neuroendocrine [n = 1]). In all 32 patients, the confirmed objective response rate (ORR) was 47% (95% CI: 26-65%). Confirmed reactions were observed in nine unique RET fusion-positive advanced cancer types. The median duration of response (DoR) was not reached, and the median follow-up time was 13 months. 73% (11/15) of responding patients are responding.
The safety of patients in this cohort is consistent with the known safety of Retevmo Selpercatinib. In this cohort, the most common treatment emergencies of any grade (≥20%) were increased aspartate aminotransferase/alanine aminotransferase, dry mouth, high blood pressure, diarrhea, fatigue, nausea, and abdominal pain. No patients in this cohort discontinued treatment due to treatment-related adverse events.
Vivek Subbiah, MD, said: “Although rare, RET fusion occurs in the’long tail’ of solid tumors other than lung cancer and thyroid cancer, and these patients have not yet received approved targeted therapies to deal with their potential genomic drivers. “Associate Professor of Cancer Therapeutics Research Center, Department of Cancer Medicine, University of Texas MD Anderson Cancer Center, and clinical medical director of the Targeted Therapy Clinical Center. “These results demonstrate the potential of Selpercatinib in this patient population and reiterate the importance of extensive genome profiling to determine the role of oncogenic drivers (including RET fusion proteins).
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
